Tag Archive for: Novo Holdings

What Next After A Year Of Innovation And Growth?

As part of its ‘Pharma Outlook for 2022’, leading healthcare publication, In Vivo, explored the outlook for US and EU venture capital funding in biopharma.  Asking whether the sector can keep the momentum going for investments, it drew on the experience and insight of prominent investors [many among them our clients,] to provide comment on […]

Novo Seeds Provides Business Update on a Record Year – Building Exceptional Companies for Global Impact

Over US$ 550 million raised by portfolio companies in 2021 IO Biotech IPO on US NASDAQ Forendo Pharma acquired for nearly US$ 1 billion Muna launched with world-leading science to advance latest scientific breakthroughs in neuroscience Adcendo raised US$ 60 million Series A to deliver next-generation Antibody-Drug Conjugates Hemab raised US$ 50 million Series A to […]

Novo Holdings to acquire Ritedose

Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire Ritedose from AGIC Capital and Humanwell. Founded in 1995 and headquartered in Columbia, S.C., The Ritedose Corporation (“Ritedose”) is a leading sterile pharmaceutical manufacturer, specialising in the use of blow-fill-seal (BFS) technology. Ritedose provides outsourced development and manufacturing of ophthalmology drugs, respiratory […]

VC Investor Panel: Building the Future Champions 

Watch a replay of the live session here or read our top takeaways below…

Novo Holdings Leads US$21M Series A Financing in BI-OMILQ

Funds will be used to support the development of pioneering mammary biotechnology to bring a novel infant feeding option to market that better meets infants’ nutritional needs Syndicate includes leading clean tech and food tech investors Copenhagen, Denmark – 20 October 2021 – Novo Holdings, a leading international life science investor, today announces it has led […]